Further prospective studies are needed on large cohorts of a homogeneous patient population (for example, IDH-wildtype and O6-methylguanine DNA methyltransferase (MGMT) promoter-unmethylated glioma) to independently assess the prognostic impact of TERT promoter mutations [47]. This evidence concerns the gene IDH2 and central nervous system cancer.